Important Notice for Pacira BioSciences Investors Regarding Class Action Lawsuit and Rights

Update for Pacira BioSciences, Inc. Investors

If you are an investor in Pacira BioSciences, Inc., it is crucial to be aware of your rights regarding a class action lawsuit. Levi & Korsinsky, LLP has issued a notification to investors regarding this legal matter, which centers on allegations of securities fraud that have impacted shareholders during a specified timeframe.

Background of the Case

The class action lawsuit targets investors who may have faced losses due to alleged fraud committed by Pacira BioSciences between August 2, 2023, and August 8, 2024. The key event leading to significant investor distress occurred on August 9, 2024, when Pacira issued a press release that outlined the unfortunate court ruling regarding its U.S. Patent No. 11,033,495 concerning Exparel. This patent is vital for the company's operations, accounting for nearly 80% of its revenue.

The ruling revealed that Pacira's patent was deemed invalid, leading to fears of increased competition from generic medications, which compelled stock prices to plummet. On that fateful day in August, shares tumbled from $22.36 to an alarming $11.70—an astounding drop of 47% in just 24 hours.

Further investigation following the announcement has led analysts to question not only the validity of this patent but also of other patents held by Pacira. This could have broader implications for the company, affecting its market standing and financial health in the future.

What Affected Investors Should Know

Investors who suffered financial losses during the stipulated timeframe have until March 14, 2025, to formally request to be appointed as lead plaintiff in the class action. However, it's essential to note that participation in any potential recovery from the lawsuit does not require one to be a lead plaintiff.

Levi & Korsinsky offers interested class members the opportunity to engage without any out-of-pocket costs. This means that if any recovery or compensation is secured, class members can benefit without incurring fees upfront. For many investors, this constitutes a chance to recover losses at no risk.

Why Choose Levi & Korsinsky

Levi & Korsinsky has a robust record in representing investors in complicated securities litigation, boasting over 20 years of experience. The firm has successfully recovered hundreds of millions of dollars for its clients and is consistently recognized as one of the leading securities litigation firms in the United States.

Associates and clients alike appreciate its dedication to vigorous representation, particularly for shareholders facing adversity in high-stakes settings.

If you find yourself impacted by this situation or simply want to explore your options regarding Pacira BioSciences, reach out to Levi & Korsinsky as soon as possible. You can contact attorney Joseph E. Levi via email at [email protected] or by phone at (212) 363-7500 for further guidance on the issue.

Levi & Korsinsky, LLP, located at 33 Whitehall Street, 17th Floor, New York, NY, is dedicated to ensuring that shareholders understand their rights and are armed with the information they need to navigate the complexities of securities fraud allegations. For more information, visit their website at www.zlk.com.

It is vital to take advantage of this opportunity if you are among those affected by the downturn of Pacira, as the timeframe to act is finite. Don't hesitate to take the necessary steps; your rights as an investor matter.